The Impact of Tumor Volume Burden Reduction for Pediatric Solid Tumors by Immune Checkpoint Inhibitors

被引：0
|
作者：
Saito, Takeshi [1 ,2 ]
Fuchimoto, Yasushi [2 ]
Fukui, Keisuke [2 ]
Shimizu, Takahiro [3 ]
Kuroda, Tatsuo [4 ]
Hirabayashi, Takeshi [1 ]
Hakamada, Kenichi [1 ]
机构：
[1] Hirosaki Univ Hosp, Dept Pediat Surg, Aomori, Japan
[2] Int Univ Hlth & Welf Hosp, Dept Pediat Surg, Otawara, Tochigi, Japan
[3] Tokai Univ, Sch Med, Dept Pediat Surg, Hiratsuka, Kanagawa, Japan
[4] Keio Univ, Sch Med, Dept Pediat Surg, Tokyo, Japan
来源：
PEDIATRIC BLOOD & CANCER | 2020年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OS35-3-4
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Impact of tumor burden on survival in patients with recurrent or metastatic head and neck cancer treated with immune checkpoint inhibitors
    Matoba, Takuma
    Minohara, Kiyoshi
    Kawakita, Daisuke
    Takano, Gaku
    Oguri, Keisuke
    Murashima, Akihiro
    Nakai, Kazuyuki
    Iwaki, Sho
    Tsuge, Hiroshi
    Tanaka, Nobukazu
    Imaizumi, Sae
    Hojo, Wataru
    Matsumura, Ayano
    Tsukamoto, Koji
    Esaki, Shinichi
    Iwasaki, Shinichi
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [32] Repurposing drugs for solid tumor treatment: focus on immune checkpoint inhibitors
    Liu, Qingxu
    Li, Long
    Qin, Wan
    Chao, Tengfei
    CANCER BIOLOGY & MEDICINE, 2023, 20 (11) : 856 - 868
  • [33] Thoracic Imaging of Solid Tumor Patients Treated with Immune Checkpoint Inhibitors
    Hammer M.M.
    Current Radiology Reports, 6 (2)
  • [34] Immune Signatures of Solid Tumor Patients Treated With Immune Checkpoint Inhibitors: An Observational Study
    Chen, Ling
    Tan, Hourui
    Geng, Ruixuan
    Li, Yifan
    Wang, Yingyi
    Li, Taisheng
    THORACIC CANCER, 2025, 16 (01)
  • [35] Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors
    Chen, Yu
    Li, Yi
    Guan, Yanfang
    Huang, Yingying
    Lin, Jing
    Chen, Lizhu
    Li, Jin
    Chen, Gang
    Pan, Leong Kin
    Xia, Xuefeng
    Xu, Ning
    Chang, Lianpeng
    Guo, Zengqing
    Pan, Jianji
    Yi, Xin
    Chen, Chuanben
    MOLECULAR ONCOLOGY, 2020, 14 (09) : 2096 - 2110
  • [36] Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors
    Heinhuis, K. M.
    Ros, W.
    Kok, M.
    Steeghs, N.
    Beijnen, J. H.
    Schellens, J. H. M.
    ANNALS OF ONCOLOGY, 2019, 30 (02) : 219 - 235
  • [37] Early mortality with immune checkpoint inhibitors (IOs) in solid tumors: An inconvenient truth?
    Winquist, Eric
    Kuruvilla, Sara
    Nichols, Anthony Charles
    Lenehan, John Gordon
    Macneil, S. Danielle
    Palma, David A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [38] Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors
    Pender, Alexandra
    Titmuss, Emma
    Pleasance, Erin D.
    Fan, Kevin Y.
    Pearson, Hillary
    Brown, Scott D.
    Grisdale, Cameron J.
    Topham, James T.
    Shen, Yaoqing
    Bonakdar, Melika
    Taylor, Gregory A.
    Williamson, Laura M.
    Mungall, Karen L.
    Chuah, Eric
    Mungall, Andrew J.
    Moore, Richard A.
    Lavoie, Jean-Michel
    Yip, Stephen
    Lim, Howard
    Renouf, Daniel J.
    Sun, Sophie
    Holt, Robert A.
    Jones, Steven J. M.
    Marra, Marco A.
    Laskin, Janessa
    CLINICAL CANCER RESEARCH, 2021, 27 (01) : 202 - 212
  • [39] Beyond monotherapy: An era ushering in combinations of PARP inhibitors with immune checkpoint inhibitors for solid tumors
    Zhou, Lin
    Wan, Yicong
    Zhang, Lin
    Meng, Huangyang
    Yuan, Lin
    Zhou, Shulin
    Cheng, Wenjun
    Jiang, Yi
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 175
  • [40] Bibliometric analysis of research trends on the combination of immune checkpoint inhibitors and PARP inhibitors in solid tumors
    Tan, Yaqian
    Song, Qi
    HELIYON, 2024, 10 (02)
12345